Search results
Results from the WOW.Com Content Network
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California, wholly owned by the Swiss multinational pharmaceutical company, the Roche Group. It became an independent subsidiary of Roche in 2009.
AIDSVAX is an experimental HIV vaccine that was developed originally at Genentech in San Francisco, California, and later tested by the VaxGen company, a Genentech offshoot. [1] The development and trials of the vaccine received significant coverage in the international media, but American trials proved inconclusive.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Help; Learn to edit; Community portal; Recent changes; Upload file
Pages in category "Genentech" The following 2 pages are in this category, out of 2 total. This list may not reflect recent changes. ...
Genentech had been able to manufacture, receive federal approval for, and market its own product, marking the successful execution of Swanson's plan to form out of Genentech a self sustainable biotech firm. [5] [6] [8] Swanson left his position as CEO in 1990, taking on the position of chairman until his retirement from Genentech in 1996. [5 ...
Emicizumab, sold under the brand name Hemlibra, is a humanized bispecific monoclonal antibody for the treatment of haemophilia A, developed by Genentech and Chugai (both organizations are subsidiaries of Hoffmann-La Roche). [4] A Phase I clinical trial found that it was well tolerated by healthy subjects. [5]
In 1993, Francis joined Genentech, Inc., of South San Francisco to try to develop a vaccine for HIV. In 1995, Francis and fellow retro-virologist Dr. Robert Nowinski spun off Genentech's HIV vaccine unit after the company had disappointing results, and founded VaxGen , based in Brisbane, California, to continue working on vaccines.
An interference between U.S. patent 4,816,567 (the original "Cabilly patent") co-issued to Genentech and City of Hope and U.S. patent 4,816,397 (the "Boss" patent) issued to Celltech resulted in the issuance of a second "Cabilly patent" to Genentech in 2001. This new patent would extend into 2018, an effective term of 29 years.